Table 4 Disease characteristics and response (MRD or clinical) at the final response assessment in patients receiving G-B in cohort 1 of the GREEN study

From: Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

Factor, n/N (%) patients

MRD negativea (blood)

MRD negativea (bone marrow)

CR/Crib

All patients

94/104 (90.4)

44/65 (67.7)

55/158 (34.8)

Binet stage A

32/32 (100)

13/18 (72.2)

19/48 (39.6)

Binet stage B+C

62/72 (86.1)

31/47 (66.0)

36/110 (32.7)

Disease bulk ≥5 cm

57/64 (89.1)

27/39 (69.2)

29/95 (30.5)

ALC ≥50 × 109/l

52/59 (88.1)

25/38 (65.8)

33/88 (37.5)

17p deletion

3/6 (50.0)

2/3 (66.7)

2/11 (18.2)

11q deletion

18/23 (78.3)

5/15 (33.3)

7/26 (26.9)

12q trisomy

18/20 (90.0)

12/14 (85.7)

8/26 (30.8)

13q deletion

32/32 (100)

13/19 (68.4)

22/52 (42.3)

CD38 positive

49/55 (89.1)

17/28 (60.7)

22/70 (31.4)

CD38 negative

37/41 (90.2)

22/30 (73.3)

22/59 (37.3)

ZAP70 positive

54/60 (90.0)

22/34 (64.7)

30/82 (36.6)

ZAP70 negative

32/36 (88.9)

17/24 (70.8)

14/47 (29.8)

IGHV mutated

31/31 (100)

12/17 (70.6)

17/44 (38.6)

IGHV unmutated

58/68 (85.3)

28/44 (63.6)

30/92 (32.6)

  1. ALC absolute lymphocyte count, CR complete response, CRi complete response with incomplete marrow recovery, G-B obinutuzumab plus bendamustine, IGHV immunoglobulin heavy variable chain, MRD minimal residual disease
  2. a Patients with evaluable (laboratory sample with a valid result at the final response assessment) MRD
  3. b Patients who achieved CR/CRi at the final response assessment in the intent-to-treat population